TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Exclusion Criteria

• •Prior treatment with TAS-102 or irinotecan
• •Anti-cancer therapy within 2 weeks of the planned first dose of study medication
• •Unresolved toxicities from prior therapy of \> grade 1, excluding alopecia or similar toxicities which are not deemed to be clinically significant or put the participant at greater risk. Grade 2 neuropathy is permitted
• •Major surgery within 4 weeks of anticipated start of therapy
• •Uncontrolled hypertension: systolic blood pressure \>= 150, diastolic blood pressure \>= 100
• •Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are allowed)
• •Arterial or venous thrombotic or embolic events within 3 months of study initiation, unless well controlled on stable anti-coagulation for \>= 2 weeks. This excludes uncomplicated catheter associated venous thrombosis
• •History of cerebrovascular or myocardial ischemia within 6 months of initiation
• •National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 grade 3 or greater hemorrhage within the past 4 weeks
• •Proteinuria \>= 2+, unless 24 hour urine collection demonstrates =\< 1 g of protein OR spot protein: creatinine demonstrates a ratio of =\< 1
• •Untreated brain metastases
• •History of abnormal glucuronidation of bilirubin (Gilbert's syndrome)
• •History of second primary malignancy within 3 years prior to enrollment, excluding in-situ cervical carcinoma, non-melanoma skin cancer or malignancy of equivalent risk which is highly unlikely to require systemic treatment in the next 2 years
• •Have known active infection which would heighten the risk of complications
• •Pregnant or nursing female participants
• •Unwilling or unable to follow protocol requirements
• •Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug